Crizotinib resistance: implications for therapeutic strategies

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Anaplastic lymphoma kinase (ALK) gene fusions were identified as oncogenic drivers in non-small-cell lung cancer (NSCLC) in 2007.
• ALK rearrangements occur in 3%-7% of NSCLC patients, particularly younger individuals with adenocarcinoma and minimal smoking history.
• Crizotinib, a tyrosine kinase inhibitor, was repurposed to treat ALK-rearranged (ALK+) NSCLC, showing initial efficacy.

Purpose of the Study:

• To review the clinical activity of crizotinib in ALK+ NSCLC.
• To describe the diverse molecular mechanisms underlying acquired resistance to crizotinib.
• To survey emerging therapeutic strategies for overcoming crizotinib resistance.

Main Methods:

• Literature review of clinical studies on crizotinib activity.
• Analysis of research identifying molecular mechanisms of crizotinib resistance.
• Survey of preclinical and clinical data on novel therapeutic agents.

Main Results:

• Crizotinib demonstrates significant initial clinical activity in ALK+ NSCLC patients.
• Multiple molecular mechanisms contribute to the development of acquired resistance to crizotinib.
• Emerging therapies show promise in targeting resistance pathways and re-sensitizing tumors to treatment.

Conclusions:

• ALK rearrangements are a validated target in a subset of NSCLC.
• Acquired resistance is a major clinical challenge limiting long-term benefit from crizotinib.
• Development of next-generation inhibitors and combination strategies is crucial for durable disease control.